ASLAN Pharmaceuticals

You are now leaving our web site.

The Website may contain links to or from other websites, over which ASLAN has no control. These linked sites are for your convenience only and you access them at your own risk.

ASLAN is not responsible for the content of the linked sites. ASLAN does not in any way endorse the linked sites.

I understand

News & Publications

Read about our latest product developments and partnerships, industry advances and events.

News

ASLAN Pharmaceuticals to present new data on Varlitinib at European Society for Medical Oncology Congress

Today, ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that an abstract on varlitinib has been accepted for poster presentation at the upcoming 2019 European Society for Medical Oncology (ESMO) Congress in Barcelona, Spain on 27 September – 1 October 2019.

For more information, please refer to the English or Chinese press release.